nSMOL Antibody BA Kit
Development of monoclonal antibodies assays by mass spectrometry
Method to quantify several simultaneously monoclonal antibodies
Assistance Publique–Hôpitauxde Paris (APHP)
-
INDUSTRY
Biopharmaceutical
-
KEYWORD
pharmaceutical management, personalized medicine, pharmacokinetics, monoclonal antibodies
-
INTRODUCTION SERVICE&PRODUCTS
nSMOL Antibody BA Kit
We interviewed Dr. Zahr Noel from APHP, Pitié Salpetrière Hospital in France, for an activity ok pharmacology dedicated to improving drug management (personalized medicine) on the project of ‘Monoclonal antibody pharmacokinetic assay and evaluation with the "nSMOL" kit and Shimadzu LCMS instrument’ starting in 2018. APHP and Shimadzu started collaborations since the project started.
Customer
Dr. Noel Zahr
Head of the "Pharmacokinetics and Therapeutic Pharmacological Monitoring" unit and the Therapeutic Drug Monitoring Laboratory in Assistance Publique–Hôpitaux de Paris (AP-HP), Pitié Salpetrière Hospital
*Affiliates and titles of the interviewee are current as of the time of reporting.
Assistance Publique–Hôpitauxde Paris (APHP)
URL https://www.aphp.fr/
could you outline the research and let us know what discovery and achievement have been made so far?
We were interested by the development of monoclonal antibodies assays by mass spectrometry, but we do not have experience in this field. In the early part of this collaboration, with the help of Shimadzu and nSMOL kit, we were able to develop quickly the dosage of Belimumab by LCMS-8060 for patients with systemic lupus erythematosus*1. Currently, we are in the process of analyzing the results to study the pharmacokinetics and pharmacokinetics / pharmacodynamics correlation for this drug. Then, we urgently developed the dosage of Tociluzumab during Covid-19 epidemic. This method allowed us to study the rate of passage of tociluzumab into the brain, and to describe the marked clinical and biological response of a targeted treatment with Tociluzumab in a patient with a severe corticoresistant CNS toxicity of immune-checkpoint inhibitors (ICI) therapy*2. Finally, our main focus of development is TDM in oncology. Thanks to this collaboration, we have developed a method to quantify several simultaneously monoclonal antibodies*3.
- Zahr, N., Amoura, Z., Beaulieu, Q., Llopis, B., Pha, M., Benameur, N., Mathian A. & Funck-Brentano, C. (2021) "Application and validation of LC-MS/MS bioanalysis of Belimumab in patients with systemic lupus erythematosus", Fundamental & Clinical Pharmacology, 35(S1), 144.
- article accepted in Neuroimmunology and Neuroinflammation Journal
- Data issues from these developments are not published yet.
Read more
You can read more in the content below
